Neurocrine Biosciences (NASDAQ:NBIX) Given New $185.00 Price Target at Morgan Stanley

Neurocrine Biosciences (NASDAQ:NBIX) had its price target raised by investment analysts at Morgan Stanley from $183.00 to $185.00 in a research report issued to clients and investors on Tuesday, Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley‘s price target would suggest a potential upside of 10.72% from the company’s previous close.

Several other research firms have also weighed in on NBIX. Piper Sandler upped their price objective on Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Tuesday. UBS Group cut their target price on Neurocrine Biosciences from $231.00 to $214.00 and set a “buy” rating for the company in a research report on Tuesday, September 29th. Stifel Nicolaus raised their target price on Neurocrine Biosciences from $188.00 to $215.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Guggenheim started coverage on Neurocrine Biosciences in a research report on Tuesday, October 6th. They issued a “buy” rating and a $207.00 price target on the stock. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $204.00 price target on shares of Neurocrine Biosciences in a research report on Friday, October 16th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $201.55.

Neurocrine Biosciences Stock Performance

Shares of NBIX stock traded up $21.74 during trading on Tuesday, hitting $167.09. 2,074,404 shares of the company were exchanged, compared to its average volume of 1,224,783. The firm has a market capitalization of $16.98 billion, a price-to-earnings ratio of 24.46, a P/E/G ratio of 0.64 and a beta of 0.36. The business’s 50-day simple moving average is $146.49 and its 200 day simple moving average is $147.45. Neurocrine Biosciences has a twelve month low of $122.14 and a twelve month high of $186.12.

Neurocrine Biosciences (NASDAQ:NBIX) last released its quarterly earnings results on Monday, November 2nd. The company reported $3.29 earnings per share for the quarter, beating analysts’ consensus estimates of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 20.91% and a return on equity of 22.43%. The business had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter last year, the firm earned $2.04 EPS. Neurocrine Biosciences’s revenue for the quarter was up 41.3% on a year-over-year basis. On average, equities analysts forecast that Neurocrine Biosciences will post 7.72 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Matt Abernethy sold 2,311 shares of the business’s stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $157.20, for a total value of $363,289.20. Following the completion of the transaction, the chief financial officer owned 42,808 shares of the company’s stock, valued at $6,729,417.60. The trade was a 5.12% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider David W. Boyer sold 826 shares of Neurocrine Biosciences stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $157.45, for a total transaction of $130,053.70. Following the completion of the transaction, the insider directly owned 8,722 shares in the company, valued at $1,373,278.90. This trade represents a 8.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 4.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds have recently modified their holdings of the company. BlackRock Inc. acquired a new stake in Neurocrine Biosciences during the 2nd quarter worth approximately $2,310,886,000. Renaissance Technologies LLC lifted its stake in Neurocrine Biosciences by 8.0% in the first quarter. Renaissance Technologies LLC now owns 2,418,897 shares of the company’s stock valued at $318,665,000 after buying an additional 180,100 shares during the period. First Trust Advisors LP grew its holdings in shares of Neurocrine Biosciences by 97.0% during the first quarter. First Trust Advisors LP now owns 959,217 shares of the company’s stock valued at $126,367,000 after buying an additional 472,408 shares during the last quarter. Bank of New York Mellon Corp purchased a new stake in Neurocrine Biosciences in the 2nd quarter valued at $117,827,000. Finally, Ieq Capital LLC purchased a new position in shares of Neurocrine Biosciences in the 2nd quarter worth approximately $107,914,000. Institutional investors and hedge funds own 92.59% of the company’s stock.

Neurocrine Biosciences News Roundup

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Strong Q3 results: Neurocrine reported adjusted earnings of $3.29 per share, well above analyst estimates ranging from $1.91 to $2.67 and up from $2.04 a year earlier. Revenue rose 41.3% year over year to approximately $1.12 billion, also exceeding expectations. Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: INGREZZA outlook raised: Management increased 2026 net sales guidance for INGREZZA (valbenazine) to $2.9 billion-$2.925 billion. The company also surpassed $1 billion in quarterly net product sales for the first time, signaling strong demand across its portfolio. Neurocrine Biosciences Crosses $1 Billion in Quarterly Product Sales
• Positive Sentiment: Analyst targets increased: Piper Sandler raised its target from $210 to $215 and maintained an “overweight” rating. Canaccord Genuity lifted its target from $210 to $220 with a “buy” rating, while Royal Bank of Canada increased its target from $187 to $190 and reiterated “outperform.” The revisions indicate analysts see additional upside following the earnings beat.
• Neutral Sentiment: Investor focus remains on execution: Earnings-call coverage highlights the company’s continued commercial momentum and diversified medicines portfolio. Investors will likely monitor whether demand remains strong enough to support the raised guidance and sustain recent earnings growth. Neurocrine Q3 2026 Earnings Call Transcript

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.